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Background: This study aims to identify dengue neutralizing antibody response in patients with dengue from a
well-characterized cohort during an outbreak in central Brazil, 2012–2013.
Methods: We analyzed paired samples from 40 patients with severe dengue and 20 patients with dengue.
Eligibility criteria were: IgM, NS1Ag and/or RT-PCR positivity and positive IgG result. Plaque reduction neutralization
test (PRNT50) from DENV-1 to DENV-4 was performed to identify serotype-specific NAbs response. An infecting
serotype was defined as ≥4-fold increase in DENV NAbs in paired samples. Monotypic response was classified as
PRNT50 ≥ 1/20 to only one DENV serotype, and multitypic response was considered to be PRNT50 ≥ 1/20 to two or
more serotypes simultaneously.
Results: Patients were mainly adults. Virological dengue infection was confirmed by RT-PCR: DENV-4(n = 14) and
DENV-1(n = 10). Forty-four out of 60(73.3 %) patients had NAbs to DENV-4, DENV-1(68.3 %), DENV-2(68.3 %) and
DENV-3(61.6 %) respectively. Fifteen percent of the cases presented monotypic response, whereas 85 % had
multitypic response. DENV-4 infected-patients presented the greatest difference in PRNT50 titers compared with
other serotypes. Pre-existing DENV NAbs was not correlated with disease severity. This was the first time that
DENV-4 was implicated in an epidemic in the region.
Conclusion: Our data indicates high exposure of multiple DENV serotypes in all age groups in the pre-dengue
vaccine era and also previous to Zika virus introduction in Brazil.
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Dengue is one of the most relevant arboviruses in the
world, endemic in more than 120 countries in tropical
and subtropical areas [1]. Dengue virus is a mosquito-
borne flavivirus with four characterized antigenically
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occur every year with ~100 million symptomatic
illnesses according to a recent modeling estimation [2].
In the American region, nearly 61 % of the 2.38 million
dengue cases were reported in Brazil in 2013 [3].
Nationwide there was evidence of an upward trend in
the number of reported dengue cases, hospitalization
and deaths in the last decade [4–6]. In central Brazil the
first dengue outbreak was registered in 1994 with the
detection of DENV-1, followed by DENV-2 (1998),
DENV-3 (2002) and DENV-4 (2011) [7, 8]. Over the last
two decades the peak of dengue transmission occurredle is distributed under the terms of the Creative Commons Attribution 4.0
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incidence rate of 4411 per 100,000 inhabitants [9].
Dengue may develop as an unapparent infection with
the majority of cases presenting mild disease, but life-
threatening conditions, death may occur [1]. Susceptible
individuals mount a specific immune response when
they are infected by one of the four DENV serotypes.
Sequential infections also occur after exposure to differ-
ent serotypes [10, 11]. DENV infection is believed to
induce a long-lasting protective immunity to homolo-
gous serotypes. In addition, due to cross-protection, a
transient immunity to heterologous serotypes may play a
beneficial role in clinical outcomes [12]. By contrast, the
viral infection mediated by antibodies (ADE) may be
amplified during a secondary infection with a heterol-
ogous serotype, leading to deleterious immune response
and disease severity [13–15].
The plaque reduction neutralization test (PRNT) is
currently the gold standard to identify dengue serotype-
specific neutralizing antibodies. This assay allows the
detection of pre-existing and/or current DENV infection
and seems to be correlated with protection [16]. In the
current study, we aimed to identify the DENV neutraliz-
ing antibody response in paired samples collected from
patients with dengue enrolled in hospital and ambula-
tory settings in central Brazil. The objective was also to
assess the correlation of pre-existing DENV neutralizing
antibodies by PRNT with dengue outcomes during the
2012–2013 outbreak. The study was conducted along-
side the first DENV-4 outbreak, examining simultaneous
co-circulation of the four serotypes in the region. The
antibody profile is crucial to understanding the risk




A clinical cohort of 452 laboratory-confirmed dengue
cases was assembled in the city of Goiania in central
Brazil (1.3 million inhabitants) [17] during the dengue
outbreak of 2012–2013. The study area also has endemic
yellow fever with high vaccination coverage (17DD
yellow fever) in the population [18]. We recruited cases
in eight public health clinics and in one public and two
private hospitals. Briefly, patients were clinically and
epidemiologically evaluated at baseline alongside with
collection of blood samples at acute phase of disease
(≤7 days of onset of symptoms) (t0). The follow-up con-
sisted of a clinical evaluation and blood collection during
a recent convalescence at 8–15 days (t1) and late conva-
lescence at 20–30 (t2) days after the onset of symptoms.
The patients were clinically classified as dengue, dengue
with warning signs (DWS) or severe dengue (SD)
according to the World Health Organization criteria [1].For the current study, dengue cases were defined by at
least one of the following tests: IgM, NS1Ag and/or RT-
PCR. At least one positive IgG result in paired sera was
required to perform PRNT.
Out of the entire cohort, we selected the first 40
patients who were diagnosed with either DWS (dengue
with warning signs) or SD (severe dengue), considering
the previously defined eligibility criteria. As a compari-
son group, we also selected the first 20 enrolled dengue
eligible patients.
Laboratory procedures
Blood samples collected during the clinical evaluation (t0,
t1 and t2) were processed, and sera were cryopreserved
according to biosafety guidelines at the Laboratory of
Molecular Biology and Immunology of Infectious Diseases
of Federal University of Goias in Goiania, Brazil.
We performed the following tests at baseline and
follow-up: hematocrit, platelet, aspartate aminotransfer-
ase (16-50U/L), alanine aminotransferase (19–41 U/L)
and albumin (3.5–5.0 g/dL); normal ranges reported in
parentheses. For hematocrit 10 % increase in paired
samples was defined hemoconcentration. The platelet
count nadir was defined as the lowest platelet value
obtained.
Specific dengue tests
Acute (t0) and convalescent (t1 or t2) paired sera were
tested by enzyme-linked immunosorbent assay (ELISA)
using Dengue IgM-capture (PanBio, Ltd, Brisbane,
Australia) and Dengue IgG Indirect (PanBio, Ltd,
Brisbane, Australia) commercial kits. The NS1Ag test
(Biorad Platelia™) and RT-PCR (Lanciotti et al., 1992)
[19] were performed in acute serum samples. All of the
tests were conducted according to the manufacturers’
instructions.
Reverse Transcriptase – Polymerase Chain Reaction (RT-
PCR)
Viral RNA was extracted from serum samples using a
purification column from the PureLink™ Viral RNA/
DNA Kit (Invitrogen, Carlsbad, CA). In one-step reverse
transcription, cDNA was obtained and amplified using
consensus primers to viral genome region (Capsid/prM).
The nested PCR was performed to amplify the products
of DNA using specific-serotypes primers to identify
DENV-1 to 4 [19]. The amplicon were visualized on
1.2 % agarose gel electrophoresis according molecular
size specific to each of the serotypes and stained with
Gel Red (Biotium, BRA).
Plaque reduction neutralization test (PRNT50)
Dengue serotype-specific neutralizing antibodies (NAbs)
were determined in paired samples by a PRNT50
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[20] and according to WHO guidelines [16]. In brief, the
PRNT50 were conducted on Vero cells seeded at the
density of 3 x 105 cells/mL in MEM (Invitrogen, USA)
with 10 % Fetal Bovine Serum (FBS) (GIBCO) in 24-well
plates (0.5 mL/well) 24 h before assay. Serum samples
were heat inactivated at 56 °C for 30 min than were
diluted with MEM (1/20 to 1/2560) onto 96-well micro-
titer plates and incubation of 100 PFU of challenge virus.
The assay was carried out using the DENV strains Brazil:
DENV-1 (PE/97-42735), DENV-2 (PE/95-3808), DENV-
3 (PE/02-95016) isolated in the State of Pernambuco,
and DENV-4 isolated in the State of Roraima in 1982.
After incubation for 1 h at 37 °C, 5 % CO2, the medium
was discharged and 50 μl of each dilution of the mixture
serum/virus was inoculated in triplicate. The plates were
then incubated at the same conditions to allow virus
adsorption. The cells were covered with 500 μl of semi-
solid medium and incubated for 7 days at 37 °C, 5 %
CO2. After discarding the semi-solid medium, the cell
monolayer was fixed with formalin, stained with crystal
violet and plaques counted. We considered a sample as
positive when NAbs levels were ≥1:20 against at least
one serotype. The reciprocal of dilution of PRNT posi-
tivity was defined based on a 50 % reduction in plaque
counts (PRNT50). To ensure accuracy and avoid inter-
test variations, all of the procedures were performed by
the same technician at a Public Health Laboratory Dr.
Giovanni Cysneiros (LACEN-GO) in Goias state with
technical supervision at the LaViTE, Centro de Pesquisas
Aggeu Magalhães/FIOCRUZ in Recife, Pernambuco.
The Brazilian institutions are part of the National
Dengue Diagnosis Network.
Definitions
The infecting serotype/current infection was defined as
follows: a) ≥ 4-fold increase in serotype-specific NAbs ti-
ters among paired sera, or b) positive serotype-specific
NAbs (PRNT50 ≥ 1/20) in a convalescent sample but as a
negative result in acute sample. Moreover, the infecting
serotype was also defined by RT-PCR in acute samples.
A monotypic response was defined by the presence of
NAbs against only one of the four DENV serotypes. A
multitypic response was defined as a concomitant detec-
tion of NAbs against two (dual), three or more
serotypes.
A primary infection was defined by detecting NAbs
against the infecting serotype in the absence of
pre-existing NAbs in paired sera. A secondary infection
was defined by detecting the infecting serotype and the
presence of preexistent heterologous NAbs.
A sequential DENV infection was identified when
there was seroconversion of NAbs for the infecting sero-
type and a detection of similar titers of heterologousNAbs in paired sera. It was not possible to determine
the sequence of infections in the presence of NAbs
against three or more serotypes.
Statistical analyses
The main characteristics of the study population were
described. The percentage of increase in hematocrit and
the platelet count nadirs were stratified by severe and
dengue cases. Albumin, AST and ALT values were cate-
gorized according to reference levels and compared
among the dengue groups. The X2 test was applied for
categorical variables, t-test to detect difference between
means, 2-tailed p < 0.05 was considered statistically
significant.
The reciprocal of dilution of PRNT50 values were log-
transformed (log base 10) after adding one (setting
PRNT <1/20 to a value of 1). The geometric mean titers
(GMT) and 95 % CIs were calculated. The median
values of the PRNT titers (log base 10) difference among
paired samples was compared using a non-parametric
test of Friedman.
Statistical analyses was performed using SPSS v.18.0
(Inc., Chicago, IL, USA) and GraphPad Prism v.6.04
(GraphPad Software, USA)
Results
Sixty subjects with paired samples of dengue confirmed
cases were selected for the PRNT50 to all four DENV
serotypes. The age range of severe dengue and dengue
patients varied from 3 to 81 years old and from 11 to
79 years old, respectively, with a statistical significant
difference in the mean ages between the groups (t-test =
5.26). There was a significant association between sever-
ity of dengue and hospitalization X2 = 6.91; p = 0.02). Six
patients had positive tourniquet test as the only
hemorrhagic manifestation and were classified as dengue
cases. Hemorrhagic manifestation was predominant
among the severe dengue cases, a statistical significant
association when compared to dengue cases (X2 = 22.85;
p < 0.01). When considering the platelet count nadir, the
severe dengue cases had a higher frequency of low plate-
lets levels (57.5 % ≤ 100 platelets/mm3) compared with
25 % in the dengue group, yielding a statistically signifi-
cant association between the groups. An increase of
10 % or more in the hematocrit levels was not signifi-
cantly different between the groups (X2 = 1.60; p = 0.34).
Higher frequencies of low albumin levels (<3.5 g/dL)
were detected among the severe dengue cases (47.5 %)
compared with the control group (20.0 %) (X2 = 4.19;
p = 0.04). Severe dengue cases presented higher
values of AST compared with the control group
(X2 = 4.07; p = 0.04) (Table 1).
In total all patients presented NAbs for one or more
DENV serotypes. Overall, 44 out of the 60 dengue
Table 1 Characteristics of dengue patients by disease severity






Age, mean SD, years 33.6 ± 18.5 47.05 ± 20.5 <0.001
Sex, ratio of females to males 2.1:1.0 0.8:1.0
Educational level, yearsc(%)
≤ 8 17(51.5) 7(41.2) 0.49
> 8 16(48.5) 10(58.8)
Raced, (%)
White 18(48.7) 7(36.8) 0.46
Mixed/Black 19(51.3) 12(63.2)
Hospitalization, (%) 20(50.0) 3(15.0) <0.01
Hemorrhagic manifestation, (%) 36(90.0) 6e(30.0) <0.01
Platelet count nadir, platelets/mm3f
> 100 16(40.0) 15(75.0) 0.02
> 50 to≤ 100 18(45.0) 5(25.0)
≤ 50 6(15.0) -
Hematocrit increase, (%)
< 10 32(80.0) 13(65.0) 0.35
≥ 10 8(20.0) 7(35.0)
Albumin, (%)
< 3.5 – low values 19(47.5) 4(20.0) 0.04
3.5–5.5 – normal values 21(52.5) 16(80.0)
AST, (%)
< 50 – normal values 13(32.5) 12(60.0) 0.04
≥ 50 – high values 27(67.5) 8(40.0)
ALT, (%)
< 41 – normal values 18(45.0) 11(55.0) 0.46
≥ 41 – high values 22(55.0) 9(45.0)
Data are the no. (%) of subjects, unless otherwise indicated; AST aspartate
aminotransferase, ALT alanine aminotransferase. Platelet count nadir was
defined as the lowest platelet value obtained
aClinically classified as dengue with warning signs or severe dengue
bX2 test was used for categorical variables
cData were missing for seven severe dengue cases and three dengue cases
dData were missing for three severe dengue cases and one dengue case
ePositive tourniquet test as the only hemorrhagic manifestation
fThe platelet count nadir was defined as the lowest platelet value obtained
Table 2 Characteristics of serotype-specific neutralizing
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DENV-1 (68.3 %), DENV-2 (68.3 %) and DENV-3
(61.6 %), considering each serotype per se. The majority
of dengue cases independent of severity had multitypic
infection (85 %). Nine out of the 40 severe dengue cases
(22.5 %) had NAbs against all four DENV serotypes
while seven out of 20 dengue cases (35.0 %) also had this
multitypic response. There is no association between
antibody response (monotypic, dual or multitypic) and
severity of disease (X2 = 0.43; p = 0.81) (Table 2).
All of the patients had positive IgG results in acute or in
convalescent serum samples according to inclusion criteria.43 out of 60 subjects were IgM positive (71.6 %); 34 were
NS1Ag positive (56.6 %). Twenty-four out of the 60
patients had a virological dengue infection confirmed by
RT-PCR with the following results: DENV-4 (n = 14) and
DENV-1 (n = 10) with negative virological results in 36
patients. At baseline, all of the patients had serum collected
within 1–7 days, except one patient whose serum was
collected at 9 days (median = 4.5 days). The range in the
number of days for the serum collection in the follow-up
period varied from 8 to 30 days with extreme values (7 days
in 1 patient and 7 patients with a range of 31–44 days) (me-
dian = 21 days). The difference of the collection dates
between convalescent and acute sera varied from 2 to
42 days (median = 16 days). Fifty-two out of 60 patients
(86.6 %) had at least a four-fold increase in neutralizing
antibodies in paired samples. Seroconversion by PRNT50
was not detected in the following eight patients: two
DENV-1 infected cases (subjects 5 and 7) by RT-PCR and
six (subjects 4, 30, 36, 39, 42, and 56) serologically-
confirmed dengue cases (IgM and/or NS1Ag) presented
with NAbs titers compatible with previous exposure with-
out recognizing the infecting serotype. One patient who
was 43 years old (subject 34) had DENV-1 and DENV-2
concurrent infections by NAbs seroconversion with type 1
confirmed by RT-PCR (Additional file 1: Table S1).
Older age groups presented with higher frequencies of
NAbs to three or more dengue serotypes compared with
Fig. 1 Neutralizing antibody response defined by PRNT50 to DENV-1 to 4 by age groups
de Teive e Argolo et al. BMC Infectious Diseases  (2016) 16:546 Page 5 of 8patients who were ≤ 15 years old. Serological evidence
for exposure to all four dengue serotypes occurred in 16
out of 60 (26.6 %) participants. All of them were sixteen
years old or more (Fig. 1). The youngest patient (3 years
old) presented with a monotypic response with a sero-
conversion to serotype 4 by PRNT50 and had a con-
firmed DENV-4 infection by RT-PCR. A nine year old
patient presenting with a DENV-4 infection by serocon-
version had also pre-existing NAbs against serotype 3.Fig. 2 Representation of reciprocal PRNT50 titers in acute (A) and convalesc
(t test p < 0,001)Five dengue patients aged 10–15 years old had the fol-
lowing: monotypic response to DENV-4 (10 years old,
subject 3); to DENV-2 (11 years old, subject 5); multity-
pic response to DENV-3/DENV-4 (11 years old, subject
4); DENV-2/DENV-4 (15 years old, subject 7) and re-
sponse to DENV-2/DENV-3/DENV-4 (13 years old, sub-
ject 6) (Additional file 1: Table S1).
The geometric mean titers (GMT) values varied
slightly from acute to convalescent sera with overlappingent (C) sera. Neutralizing Abs titers to DENV-4 among paired samples
de Teive e Argolo et al. BMC Infectious Diseases  (2016) 16:546 Page 6 of 8confidence intervals for DENV-1, 2 and 3. Neutralizing
Abs titers to DENV-4 were higher in the convalescent
sera (GMT = 281.83; IC95% 154.88-512.86) compared
with the acute sera (GMT = 60.63; IC95% 36.30–97.72)
(p < 0,001) (Fig. 2). We presented the box-plot distribu-
tion of the difference between the NAbs titers (log10)
measured in convalescent and acute samples for all
DENV serotypes (Friedman Test X2 = 31.76; p < 0.001).
The difference in the DENV-4 NAbs titers (log10) in
paired samples varied from zero to 2.41; IQR (0.0–1.2)
and median value of 0.60. Our results showed that the
DENV-4 infected patients presented with the highest
difference in PRNT50titers compared with the other
serotypes (Additional file 2: Figure S1).
Figure 3 presents with individual NAbs titers stratified
by DENV-1 or DENV-4 infected cases confirmed by RT-
PCR. Seroconversion to serotype 4 by PRNT50 was
detected among all DENV-4 virologically-confirmedFig. 3 Graphical representation PRNT50 titers paired sera among
patients infected by DENV-1 or DENV-4. Legend: PRNT50 titers
(log10) in paired sera stratified for acute (A) or convalescent (C)
phase of disease among patients infected by DENV-1 or DENV-4
determined by RT-PCR. (A) 10 patients infected by DENV-1; (B) 14
patients infected by DENV-4. Line represents meanpatients. Among the 10 DENV-1 infected patients, eight
also showed seroconversion to serotype 1. Two patients
did not present with seroconversion in NAbs titers to
serotype 1 probably due to the small lag time (≤7 days)
between sample collections.
Discussion
Our study showed evidence of the simultaneous circula-
tion of all four DENV serotypes during the major
outbreak in the year 2013 in central Brazil. The dengue
patients presented with a high seroprevalence of neutral-
izing antibodies against DENV-1, DENV-2, DENV-3
and/or DENV-4 detected by PRNT50 mainly as a multi-
typic response. These results may reflect cumulative
exposure to the circulating dengue virus in the study
setting. In our study, DENV-4 was the predominant
serotype during the outbreak in consonance with the
main dengue virus isolated in the same period by
surveillance data [8].
Most dengue patients presented with pre-existing
NAbs levels for at least two DENV serotypes simultan-
eously. A multitypic response was predominant among
children and adults suggesting early and continuous
transmission of DENV serotypes in the study setting.
Our results of a high frequency of multitypic response
are in line with a previous population-based study in the
northeast area of Brazil (2005–2006) [21].
In the present study, there was a high frequency of
multitypic responses independently of the severity of the
dengue cases. Tertiary or quaternary immune responses
were similarly distributed between the severe dengue
and control group.
One female adult (43 years old) recruited in the
hospital was classified as a severe dengue case and had
concurrent infections by DENV-1 and DENV-2 accord-
ing to the PRNT50 results. DENV-1 was detected by
RT-PCR, but DENV-2 was not, probably due to lower
viral load of this serotype. The regional epidemiological
scenario seems to be compatible with other studies that
have also described the occurrence of concurrent dengue
infections mainly during dengue outbreaks in hyperen-
demic areas with co-circulation of all four DENV
serotypes in Asia [22–25] and in the Americas [26–28].
To our knowledge, this is the first concurrent dengue
infection reported in Goias state, central Brazil.
Several recent studies have noted potential variations
in PRNT50 assay such as virus strains, cell linage and
other test components that may influence detection,
quantification of NAbs titers with possible effects in
PRNT50 results and comparability among studies [29–31].
In our study, we analyzed serotype-specific NAbs titers for
the subset of patients with virological confirmation
(RT-PCR). Subjects with the infecting DENV-1 or DENV-
4 serotypes defined by PRNT50 had the same virological
de Teive e Argolo et al. BMC Infectious Diseases  (2016) 16:546 Page 7 of 8marker (DENV-1 or DENV-4) by RT-PCR suggesting the
consistency of the assays performed. Our data also
suggested a booster of pre-existing NAbs during a
heterologous DENV infection as described in other
studies [32, 33]. The need of paired samples to diagnose
dengue infections by PRNT50 limits its application in
clinical settings [1, 34, 35].
One of the constraints of the present study is the small
sample size. PRNT consists of a laborious technique that
requires a long time to run and technical skilled
personnel, which limits its use in large-scale studies [16].
Our results represent a NAbs response in symptomatic
dengue patients recruited in ambulatory and hospital
settings, showing a point-of care situation. We are aware
that our results should be interpreted with caution and
may not be extrapolated to other Brazilian regions.
However, this is a timely study that characterized the
dengue specific-serotype immune response during a
large dengue outbreak. It highlights the high frequency
of multitypic response pattern in all age groups.
This paper adds knowledge about serotype-specific
antibody profile in dengue patients during a DENV-4
outbreak in central Brazil. To our knowledge this is the
first evidence of multiple dengue infections in a clinical
cohort of severe and non-severe dengue cases in this
setting.
Conclusions
Our data indicates high exposure of multiple DENV se-
rotypes in all age groups in the pre-dengue vaccine era
and also previous to Zika virus introduction in Brazil.
This is essential information for future dengue vaccines
programs.Additional files
Additional file 1: Table S1. Individual data of patients according to
specific dengue tests, serotype-specific reciprocal PRNT50 titers and
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Additional file 2: Figure S2. Difference between PRNT50 titers paired
samples. Boxes encompass 50 % of the distribution; line represents
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